# OSTEOMYELITIS THERAPY MONITORED BY ANTIBODIES, WBC & MRI

> **NIH NIH R01** · INDIANA UNIVERSITY INDIANAPOLIS · 1992 · $193,428

## Abstract

Osteomyelitis commonly occurs as a complication of bone surgery, open
fracture, diabetic foot ulcer, penetrating wound, or similar condition.
When superimposed upon one of these processes osteomyelitis is a difficult
clinical problem which routine radiographic and the more sensitive nuclear
medicine techniques often fail to diagnose.  The lack of a sensitive and
specific diagnostic tool can cause an unnecessary delay in the institution
of proper therapy or the institution of unnecessarily aggressive and
expensive therapy.

We and others have utilized a variety of diagnostic algorithms with
radioactive compounds and radiolabeled white blood cells to aid in the
diagnosis of complicating osteomyelitis.  Several methods exist for
isolating white blood cells which differ considerably in the complexity of
cell separation and the final cell purity.  At least five different
lipid-soluble Indium chelates have been used to label the cells.  We
propose to use four different labeled white cell preparations along with
Indium-111 chloride alone to study a well documented canine model of
osteomyelitis.  This study will allow us to:  1) Determine the sensitivity
and specificity of each of these agents during the progression of
osteomyelitis from the acute to chronic stage.  2) Compare image quality
both subjectively and objectively for each preparation.  3) Assess the
usefulness of Indium-111 chloride alone as an imaging agent for
osteomyelitis.  4) Choose the best cell type(s) to be isolated and labeled
to diagnose each stage of osteomyelitis.  5) Determine the effect of
antibiotic therapy on the ability of these agents to diagnose osteomyelitis
and/or its resolution.

Finally, this study will provide insight into the mechanism(s) of
Indium-111 localizaation.  By analyzing the distribution of radioactivity
in the circulating blood cellular components and in the plasma, we hope to
determine the in vivo stability of the Indium-111 labeled cells and the
(bio)chemical form of any non-cellbound activity.

The results of this study should allow one to select the optimum Indium-111
agent for the diagnosis of the stages of osteomyelitis.  If limited to only
one of these radiopharmaceuticals, one will better understand the
advantages and limitations of that agent.  A better understanding of the
mechanisms of localization of the present "state-of-the-art" agents may aid
in the future development of more effective radiopharmaceuticals for the
detection of osteomyelitis.

## Key facts

- **NIH application ID:** 3157609
- **Project number:** 5R01AR036460-07
- **Recipient organization:** INDIANA UNIVERSITY INDIANAPOLIS
- **SAM.gov UEI:** SHHBRBAPSM35
- **Principal Investigator:** DONALD S SCHAUWECKER
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 1992
- **Award amount:** $193,428
- **Award type:** 5
- **Project period:** 1986-01-01 → 1994-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/3157609

## Citation

> US National Institutes of Health, RePORTER application 3157609, OSTEOMYELITIS THERAPY MONITORED BY ANTIBODIES, WBC & MRI (5R01AR036460-07). Retrieved via MORVS 2026-10-24 from https://api.morvs.ai/grant/nih/3157609. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*